Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update Nanotech Investing
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury Nanotech Investing
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results Nanotech Investing
Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer Nanotech Investing
Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026 Nanotech Investing
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference Nanotech Investing
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign Nanotech Investing
Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma Technology Investing
